Last update 13 Nov 2024

ISM-5043

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ISM024-148, ISM5043, MEN-2312
+ [1]
Target
KAT6A
Mechanism
KAT6A inhibitors(lysine acetyltransferase 6A inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Advanced breast cancerER-positive/HER2-negative Breast CancerSolid tumor
Inactive Indication-
Originator Organization
InSilico Medicine Hong Kong Ltd.InSilico Medicine Hong Kong Ltd.Startup
Active Organization
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.A. Menarini Industrie Farmaceutiche Riunite SRLA. Menarini Industrie Farmaceutiche Riunite SRLInSilico Medicine Hong Kong Ltd.InSilico Medicine Hong Kong Ltd.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ISM-5043
NCT06638307 / RecruitingPhase 1
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
100 Clinical Results associated with ISM-5043
Login to view more data
100 Translational Medicine associated with ISM-5043
Login to view more data
100 Patents (Medical) associated with ISM-5043
Login to view more data
100 Deals associated with ISM-5043
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 1
US
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
Advanced breast cancerPhase 1
FR
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
Advanced breast cancerPhase 1
DE
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
Advanced breast cancerPhase 1
IT
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
Advanced breast cancerPhase 1
KR
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
Advanced breast cancerPhase 1
ES
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
25 Oct 2024
ER-positive/HER2-negative Breast CancerPhase 1-
Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.
-
Solid tumorPhase 1-
A. Menarini Industrie Farmaceutiche Riunite SRLA. Menarini Industrie Farmaceutiche Riunite SRL
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free